Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells

Effective new therapies are urgently needed for the treatment of multiple myeloma (MM), an incurable hematological malignancy. In this study, we evaluated the effects of piperlongumine on MM cell proliferation both in vivo and in vitro. Piperlongumine inhibited the proliferation of MM cells by inducing cell apoptosis and blocking osteoclastogenesis. Notably, piperlongumine also reduced bortezomib resistance in MM cells. In a disseminated MM mouse model, piperlongumine prolonged the survival of tumor-bearing mice without causing any obvious toxicity. Mechanistically, piperlongumine inhibited the STAT3 signal pathway in MM cells by binding directly to the STAT3 Cys712 residue. These findings suggest that the clinical use of piperlongumine to overcome bortezomib resistance in MM should be evaluated.

• Publication year

  2016

• Venue

  OncoTarget

• Publication date

  2016-09-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.18632/oncotarget.11988PMID 27634873PMCID 5341994
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review).

  2016cited by this paper
• Sprouty2 regulates proliferation and survival of multiple myeloma by inhibiting activation of the ERK1/2 pathway in vitro and in vivo.

  2016cited by this paper
• The Proteasome Inhibitor Carfilzomib Suppresses Parathyroid Hormone-induced Osteoclastogenesis through a RANKL-mediated Signaling Pathway*

  2015cited by this paper
• Targeting the bone marrow microenvironment in multiple myeloma

  2015cited by this paper
• Piperlongumine induces apoptotic and autophagic death of the primary myeloid leukemia cells from patients via activation of ROS-p38/JNK pathways

  2015cited by this paper
• Eriocalyxin B Inhibits STAT3 Signaling by Covalently Targeting STAT3 and Blocking Phosphorylation and Activation of STAT3

  2015cited by this paper
• Alantolactone induces G1 phase arrest and apoptosis of multiple myeloma cells and overcomes bortezomib resistance

  2015cited by this paper
• Piperlongumine selectively kills hepatocellular carcinoma cells and preferentially inhibits their invasion via ROS-ER-MAPKs-CHOP

  2015cited by this paper
• Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines

  2014cited by this paper
• Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death

  2014cited by this paper
• Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization

  2014cited by this paper
• Piperlongumine induces cell death through ROS-mediated CHOP activation and potentiates TRAIL-induced cell death in breast cancer cells

  2014cited by this paper
• Aspirin inhibits proliferation and induces apoptosis of multiple myeloma cells through regulation of Bcl‐2 and Bax and suppression of VEGF

  2014cited by this paper
• Piperlongumine Inhibits Migration of Glioblastoma Cells via Activation of ROS-Dependent p38 and JNK Signaling Pathways

  2014cited by this paper
• Proteasome inhibitors in acute leukemia

  2014influential reference
• Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells

  2014cited by this paper
• DRUG-REPOSITIONING SCREENING IDENTIFIED PIPERLONGUMINE AS A DIRECT STAT3 INHIBITOR WITH POTENT ACTIVITY AGAINST BREAST CANCER

  2014cited by this paper
• Proteasome inhibitors in acute leukemia

  2014cited by this paper
• Synthesis and biological evaluation of isoprenylated coumarins as potential anti-pancreatic cancer agents.

  2014cited by this paper
• Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics.

  2014influential reference
• Synthesis and biological evaluation of piperlongumine derivatives as potent anti-inflammatory agents.

  2014cited by this paper
• Piperlongumine inhibits the proliferation and survival of B-cell acute lymphoblastic leukemia cell lines irrespective of glucocorticoid resistance.

  2014cited by this paper
• Piperlongumine as a potential activator of AMP-activated protein kinase in HepG2 cells

  2014cited by this paper
• Piperlongumine inhibits NF‐κB activity and attenuates aggressive growth characteristics of prostate cancer cells

  2014cited by this paper
• Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy.

  2013cited by this paper
• Piperlongumine induces autophagy by targeting p38 signaling

  2013cited by this paper
• Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells.

  2013cited by this paper
• Bone Marrow Microenvironment in Multiple Myeloma Progression

  2012cited by this paper
• Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells

  2012cited by this paper
• Selective killing of cancer cells with a small molecule targeting stress response to ROS

  2011cited by this paper
• Emerging therapies for the treatment of relapsed or refractory multiple myeloma

  2011cited by this paper
• The novel histone deacetylase inhibitor, AR‐42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells

  2011cited by this paper
• The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival

  2011cited by this paper
• THE IMMUNOPROTEASOME, THE 20S PROTEASOME, AND THE PA28{alpha}{beta} PROTEASOME REGULATOR ARE OXIDATIVE STRESS-ADAPTIVE PROTEOLYTIC COMPLEXES

  2010cited by this paper
• THE IMMUNOPROTEASOME, THE 20S PROTEASOME, AND THE PA28αβ PROTEASOME REGULATOR ARE OXIDATIVE STRESS‐ADAPTIVE PROTEOLYTIC COMPLEXES

  2010cited by this paper
• Antiplatelet activities of newly synthesized derivatives of piperlongumine

  2008cited by this paper
• MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

  2007cited by this paper
• PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells.

  2007cited by this paper
• Proteasome inhibitor bortezomib for the treatment of multiple myeloma

  2006cited by this paper
• RANK ligand and osteoprotegerin in myeloma bone disease.

  2003influential reference
• The proteasome: a novel target for cancer chemotherapy

  2002cited by this paper
• Ubiquitin‐mediated proteolysis: biological regulation via destruction

  2000cited by this paper
• Three-dimensional structure of the Stat3β homodimer bound to DNA

  1998cited by this paper
• P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo.

  1996cited by this paper

• Computational Drug Repurposing Across the Multiple Myeloma Spectrum: From MGUS to MM

  2025cites this paper
• Piperlongumine induces meningioma cell death via the ROS-mediated endoplasmic reticulum stress and the alteration of the ubiquitin-proteasome system

  2025cites this paper
• Bone marrow mesenchymal stem cell derived exosomal miR-361-5p reversed the effect of bortezomib on multiple myeloma.

  2025cites this paper
• Migrasomes in the Tumor Microenvironment: Functional Roles and Therapeutic Potential.

  2025cites this paper
• Piplartine eliminates CD34 + AML stem/progenitor cells by inducing oxidative stress and suppressing NF-κB signalling

  2024cites this paper
• Piperlongumine inhibits hepatocellular carcinoma growth by modulating GSTP1 and restraining the STAT3 signaling pathway

  2024cites this paper
• The Antitumor Activity of Piplartine: A Review

  2023influential citation
• Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition

  2023cites this paper
• Molecular Modeling and In Vitro Evaluation of Piplartine Analogs against Oral Squamous Cell Carcinoma

  2023influential citation
• Piperlongumine, a piper alkaloid, enhances the efficacy of doxorubicin in breast cancer: involvement of glucose import, ROS, NF-κB and lncRNAs

  2022cites this paper
• Piperlongumine combined with vitamin C as a new adjuvant therapy against gastric cancer regulates the ROS–STAT3 pathway

  2022cites this paper
• Multigram Scale Synthesis of Piperarborenines C-E

  2022cites this paper
• Piperlongumine and bortezomib synergically inhibit cholangiocarcinoma via ER stress–induced cell death

  2022cites this paper
• Piperlongumine overcomes imatinib resistance by inducing proteasome inhibition in chronic myelogenous leukemia cells.

  2022cites this paper
• Meta analysis of bioactive compounds, miRNA, siRNA and cell death regulators as sensitizers to doxorubicin induced chemoresistance

  2022cites this paper
• Piperlongumine Inhibits Titanium Particles-Induced Osteolysis, Osteoclast Formation, and RANKL-Induced Signaling Pathways

  2022cites this paper
• Multigram Scale Total Synthesis of Piperarborenines C-E

  2021cites this paper
• Piplartine (piperlongumine), oxidative stress, and use in cancer

  2021cites this paper
• The promising potential of piperlongumine as an emerging therapeutics for cancer

  2021cites this paper
• Piperlongumine increases the apoptotic effect of doxorubicin and paclitaxel in a cervical cancer cell line

  2020cites this paper
• Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent.

  2020cites this paper
• Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers

  2020cites this paper
• Platycodin D inhibits proliferation, migration and induces chemosensitization through inactivation of the NF‐κB and JAK2/STAT3 pathways in multiple myeloma cells

  2019cites this paper
• Role of Phytochemicals in Cancer Prevention

  2019cites this paper
• Synergistic anticancer activity of doxorubicin and piperlongumine on DU-145 prostate cancer cells - The involvement of carbonyl reductase 1 inhibition.

  2019cites this paper
• Novel activators and small-molecule inhibitors of STAT3 in cancer.

  2019cites this paper
• Resistance of Targeted Therapies Excluding Antibodies for Lymphomas

  2018influential citation
• Proteasome Inhibitors with a Focus on Bortezomib

  2018cites this paper
• Piperlongumine as anticancer agent: The story so far about killing many birds with one stone.

  2018cites this paper
• Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model

  2018cites this paper
• Piperlongumine derivative, CG-06, inhibits STAT3 activity by direct binding to STAT3 and regulating the reactive oxygen species in DU145 prostate carcinoma cells.

  2018cites this paper
• An Unexpected Journey: A Medicinal Chemistry Exploration through the Realm of Protein Tyrosine Phosphatases, Signal Transducers, and Receptor Tyrosine Kinases

  2017cites this paper
• Adipose-derived mesenchymal stem cells promote osteosarcoma proliferation and metastasis by activating the STAT3 pathway

  2017cites this paper
• Novel piplartine-containing ruthenium complexes: synthesis, cell growth inhibition, apoptosis induction and ROS production on HCT116 cells

  2017cites this paper